Posted 12/18/2016 4:14 AM (GMT 0)
I am curious to know what the members of the forum think about this study "Use of Escherichia coli Nissle 1917 producing recombinant colicins for treatment of IBD patients"
https://www.ncbi.nlm.nih.gov/pubmed/27372848
It argues that the largest proportion of people with UC are infected with Adherent-Invasive Escherichia coli strains.
So first--is that true? Has anyone heard of this?
The study goes on to say that "the application of E. coli Nissle 1917 strain as a carrier for specific recombinant colicins against AIEC strains, could probably cause a long-lasting remission of inflammation in CD and UC patients."
I am hopeful--that would be great if some iteration of Mutaflor, modified to carry colincins (whatever they are!) could be helpful. But I am also a little suspicious. The article has 1 author and is published in "Medical Hypothesis".
Thoughts?